Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)

NCT04397497 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Covid-19
Acute Respiratory Failure
ARDS, Human
Sars-CoV2
Viral Pneumonia

Interventions

DRUG: Mavrilimumab
DRUG: Placebo

Sponsor

Ospedale San Raffaele